Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MGAM | O43451 | 1/20 | 0.56 |
| ▸ | SI | P14410 | 1/20 | 0.56 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.56 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL6720383 | 1.00 | GAA (0.56) | GAAMGAMSIMGAM2CYP4F2 | |
| Acetic Acid SCHEMBL3156541 | 1.00 | GAA (0.56) | GAAMGAMSIMGAM2CYP4F2 | |
| Acetic Acid SCHEMBL413364 | 1.00 | GAA (0.56) | GAAMGAMSIMGAM2CYP4F2 | |
| Acetic Acid SCHEMBL6311569 | 1.00 | GAA (0.56) | GAAMGAMSIMGAM2CYP4F2 | |
| Acetic Acid SCHEMBL8521751 | 1.00 | GAA (0.56) | GAAMGAMSIMGAM2CYP4F2 | |
| Acetic Acid SCHEMBL146529 | 1.00 | GAA (0.56) | GAAMGAMSIMGAM2CYP4F2 | |
| Acetic Acid SCHEMBL370017 | 1.00 | GAA (0.56) | GAAMGAMSIMGAM2CYP4F2 | |
| Acetic Acid SCHEMBL787505 | 1.00 | GAA (0.56) | GAAMGAMSIMGAM2CYP4F2 | |
| Acetic Acid SCHEMBL1080927 | 1.00 | GAA (0.56) | GAAMGAMSIMGAM2CYP4F2 | |
| Acetic Acid SCHEMBL988151 | 1.00 | GAA (0.56) | GAAMGAMSIMGAM2CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118324715-A | Compounds, compositions, and methods of use thereof | 艾勒维生技公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240173267-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | ONCORUS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| CN-117750962-A | Compounds, compositions, and methods of use thereof | 艾勒维生技公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-113423709-B | Triazinone imidazole compound and medical application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-113087718-B | Thienopyrimidinone compounds and medical application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| EP-4291201-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | Oncorus, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| CN-116354927-A | HDAC degradation agent using alkane or fatty acid as connecting chain, preparation method and application thereof | 杭州医学院 | 2023-06-30 | — | — | CN | disclosed |
| CN-102675367-A | Compound containing phosphorus oxy group and pyridine unit and preparation method thereof | DONGGUAN CAIXIAN ORGANIC LIGHT EMITTING TECHNOLOGY CO LTD | 2012-09-19 | — | — | CN | disclosed |
| US-20100256333-A1 | Peptide-Based Beta Turn Mimetics | UNIVERSITY OF MANITOBA (CA) | 2010-10-07 | — | — | US | disclosed |
| CN-1314673-C | Multidentate oxazoline ligand having chirality and its compounding product with main group metal or transition metal, synthesis method and its use | SHHANGHAI INST OF ORGANIC CHEM (CN) | 2007-05-09 | — | — | CN | disclosed |
| CN-1513847-A | Multidentate oxazoline ligand having chirality and its compounding product with main group metal or transition metal, synthesis method and its use | 中国科学院上海有机化学研究所 | 2004-07-21 | — | — | CN | disclosed |
| US-6642237-B1 | Inhibitors of HIV protease and inhibitors of HIV replication, used in the prevention or treatment of infection by HIV and treatment for AIDS | MERCK & CO., INC. | 2003-11-04 | — | — | US | disclosed |
| EP-0970071-A1 | 2-PEPERAZINONE-1-ACETIC ACID DERIVATIVES AND THEIR USE | Takeda Chemical Industries, Ltd. (JP) | 2000-01-12 | — | — | EP | disclosed |
| CN-1218460-A | Substituted 4-hydroxy-phenylalcanoic acid derivatives with activity to ppar-'gamma' | GLAXO GROUP LTD (GB) | 1999-06-02 | — | — | CN | disclosed |
| WO-1998039324-A1 | 2-PEPERAZINONE-1-ACETIC ACID DERIVATIVES AND THEIR USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-11 | — | — | WO | disclosed |
| US-5389663-A | Fungicides | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-02-14 | — | — | US | disclosed |
| EP-0510700-A2 | Azole compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | GAA 3749/4885MGAM 4534/4885SI 2970/4885 |
| US-20100256333-A1 | Peptide-Based Beta Turn Mimetics | VIP, PTMA, PREP | GAA 3329/4885MGAM 3661/4885SI 221/4885 |
| US-20240173267-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | POLRMT, POLN, NSUN2 | GAA 917/4885MGAM 3922/4885SI 3128/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | GAA 3749/4885MGAM 4534/4885SI 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.